Drug Insights

Navigating Health Information: How to Use Synapse to Search for Amiodarone

27 February 2024
2 min read

Amiodarone, also known as CORDARONE, is an antiarrhythmic drug developed in 1961 by chemists Tondeur and Binon. By 1980, it was commonly prescribed throughout Europe for the treatment of arrhythmias. In December 1985, due to the threat of a cut-off from European companies, amiodarone was approved by the FDA for the treatment of arrhythmias, even though it had not undergone rigorous randomized clinical trials. Amiodarone is considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. It blocks sodium and myocardial potassium channels, contributing to slowing of conduction and prolongation of refractoriness. CORDARONE is indicated for the treatment of life-threatening ventricular fibrillation and unstable tachycardia in adults who have not responded to other antiarrhythmics. Click on the image below to begin the exploration journey of Amiodarone through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Initial Dosing of Tegavivint in Refractory Advanced Liver Cancer Study Begins
Latest Hotspot
3 min read
Initial Dosing of Tegavivint in Refractory Advanced Liver Cancer Study Begins
27 February 2024
Iterion Therapeutics stated that initial dosing has commenced in an early to mid-stage study of their drug Tegavivint for advanced liver cancer cases unresponsive to previous systemic therapies.
Read →
Teva Unveils Fresh Evidence for Anti-TL1A ('574) Antibody's Safe Use, Comfort and Efficacy at ECCO's 2024 Event
Latest Hotspot
4 min read
Teva Unveils Fresh Evidence for Anti-TL1A ('574) Antibody's Safe Use, Comfort and Efficacy at ECCO's 2024 Event
27 February 2024
Teva Pharmaceuticals has released encouraging initial results concerning the safety, patient tolerance, and pharmacokinetic profile of its investigational product known as anti-TL1A (TEV-’574).
Read →
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Lidocaine
Drug Insights
2 min read
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Lidocaine
27 February 2024
Lidocaine,the first amino amide–type local anesthetic,as opposed to the amino ester-type local anesthetics that were used before it, was originally called "xylocaine" .
Read →
NextPoint Therapeutics Begins Clinical Trial for NPX887 Targeting HHLA2+ Solid Tumors
Latest Hotspot
3 min read
NextPoint Therapeutics Begins Clinical Trial for NPX887 Targeting HHLA2+ Solid Tumors
27 February 2024
NextPoint Therapeutics Reveals Initiation of Early-Stage Clinical Study with First Subject Receiving NPX887 for Solid Tumors Containing HHLA2, an Innovative Treatment Aiming to Revitalize Worn-Out T and NK Cells.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.